Drug Quality and Security Act
Latest action · Nov 27, 2013 Became Public Law No: 113-54.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedSep 27, 2013
- Passed HouseSep 28, 2013
- Passed SenateNov 18, 2013
- To the PresidentNov 21, 2013
- Became lawNov 27, 2013Public Law 113-54
Summary
(This measure has not been amended since it was introduced. The summary has been expanded because action occurred on the measure.)
Drug Quality and Security Act - Title I: Drug Compounding - Compounding Quality Act - (Sec. 102) Amends the Federal Food, Drug, and Cosmetic Act (FFDCA) with respect to the regulation of compounding drugs. Exempts compounded drugs from new drug requirements, labeling requirements, and track and trace requirements if the drug is compounded by or under the direct supervision of a licensed pharmacist in a registered outsourcing facility and meets applicable requirements.
Establishes annual registration requirement for any outsourcing facility. Requires a facility to report biannually to the Secretary of Health and Human Services (HHS) on what drugs are compounded in the facility and to submit adverse event reports. Subjects such facilities to a risk-based inspection schedule.
Requires the Secretary to: (1) publish a list of drugs presenting demonstrable difficulties for compounding that are reasonably likely to lead to an adverse effect on the safety or effectiveness of the drug, taking into account the risk and benefits to patients; and (2) convene an advisory committee on compounding before creating the list.
Requires the Secretary to assess an annual establishment fee on each outsourcing facility and a reinspection fee, as necessary.
(Sec. 103) Prohibits the resale of a compounded drug labeled “not for resale,” or the intentional falsification of a prescription for a compounded drug. Deems a compounded drug to be misbranded if its advertising or promotion is false or misleading in any particular.
(Sec. 105) Requires the Secretary to receive submissions from state boards of pharmacy: (1) describing any disciplinary actions taken against compounding pharmacies or any recall of a compounded drug, and (2) expressing concerns that a compounding pharmacy may be violating the FFDCA.
(Sec. 106) Revises compounding pharmacy requirements to repeal prohibitions on advertising and promotion of compounded drugs by compounding pharmacies and repeal the requirement that prescriptions filled by a compounding pharmacy be unsolicited.
(Sec. 107) Requires the Comptroller General (GAO) to report on pharmacy compounding and the adequacy of state and federal efforts to assure the safety of compounded drugs.
Title II: Drug Supply Chain Security - Drug Supply Chain Security Act - (Sec. 202) Establishes requirements to facilitate the tracing of prescription drug products through the pharmaceutical supply distribution chain.
Requires the Secretary to establish standards for the exchange of transaction documentation, which shall include transaction information, transaction history, and transaction statements.
Requires the Secretary to establish processes to: (1) provide waivers of requirements, including for undue economic hardship or emergency medical reasons; (2) provide exceptions to requirements relating to product identifiers if a product is packaged without sufficient space to bear the information; and (3) determine other products or transactions that should be exempt from the requirements of this Act.
Establishes requirements for drug manufacturers, wholesalers, dispensers, and repackagers to ensure that all prior transaction information is provided at each transfer of ownership.
Requires a manufacturer, wholesale distributor, dispenser, and repackager, in the event of a recall or for the purpose of investigating a suspect product or an illegitimate product, to provide within a reasonable time the applicable transaction documentation upon request by the Secretary or other appropriate federal or state official.
Requires a manufacturer or repackager to affix or imprint a product identifier on each package and homogenous case intended to be introduced in a transaction into commerce. Excepts from this requirement with respect to unique device identifiers any products required to have a standardized numerical identifier.
Requires a manufacturer, wholesale distributor, dispenser, or repackager to ensure that each of its trading partners is authorized.
Requires a manufacturer, wholesale distributor, dispenser, and repackager to implement systems to: (1) investigate suspect products; and (2) handle illegitimate products, including through quarantine, disposal, and appropriate notice to the Secretary and, as necessary, trading partners.
Requires manufacturers, wholesale distributors, and repackagers to verify returned products before further distribution.
(Sec. 203) Prescribes additional requirements related to the tracing of products at the package level (enhanced drug distribution security) which shall go into effect ten years after enactment of this Act.
Authorizes a dispenser to enter into a written agreement with a third party, including an authorized wholesale distributor, that requires the third party to maintain confidentially any information and statements required to be maintained. Requires the Secretary to provide for alternative methods of compliance with such additional drug distribution security requirements.
Directs the Secretary to contract with a private, independent consulting firm with expertise to conduct a technology and software assessment that looks at the feasibility of dispensers with 25 or fewer full-time employees conducting interoperable, electronic tracing of products at the package level.
Requires the Secretary to: (1) establish one or more pilot projects and hold public meetings to enhance the safety and security of the pharmaceutical distribution supply chain, (2) issue a final guidance document that outlines and makes recommendations with respect to the system attributes necessary to enable secure tracing at the package level, and (3) identify and make recommendations with respect to the standards necessary for adoption in order to support the secure interoperable electronic data exchange among the pharmaceutical distribution supply chain that comply with a form and format developed by a widely recognized international standards development organization.
(Sec. 204) Requires the Secretary to establish standards for the licensing of wholesale distributors and third party logistics providers.
(Sec. 205) Preempts state and local requirements related to tracing drugs through the distribution system, and licensure of wholesale distributors and third party logistics providers.
(Sec. 206) Subjects violations of this Act to specified criminal and civil penalties.
Deems misbranded any drug failing to bear its required product identifier.
Recorded votes 1
Newest first. Open one to see how every member voted.
| Roll call | Question | Result | Date |
|---|---|---|---|
| Senate 234 | On the Cloture Motion H.R. 3204 | Cloture Motion Agreed to97–1 | Nov 12, 2013 |
Cosponsors 10
Members who signed on, in the order they did. All signed on Sep 27, 2013.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-CO | Diana DeGette | Original | Sep 27, 2013 |
| D-NJ | Frank Pallone, Jr. | Original | Sep 27, 2013 |
| D-TX | Gene Green | Original | Sep 27, 2013 |
| R-VA | H. Morgan Griffith | Original | Sep 27, 2013 |
| D-CA | Henry A. Waxman | Original | Sep 27, 2013 |
| D-UT | Jim Matheson | Original | Sep 27, 2013 |
| D-MI | John D. Dingell | Original | Sep 27, 2013 |
| R-PA | Joseph R. Pitts | Original | Sep 27, 2013 |
| R-OH | Robert E. Latta | Original | Sep 27, 2013 |
| R-PA | Tim Murphy | Original | Sep 27, 2013 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred Sep 27, 2013 |
Actions 28
Everything that happened, newest first.
- Nov 27, 2013Signed by President.
- Nov 27, 2013Became Public Law No: 113-54.
- Nov 21, 2013Presented to President.
- Nov 18, 2013Considered by Senate. (consideration: CR S8071-8076)
- Nov 18, 2013Cloture motion withdrawn by unanimous consent in Senate. (consideration: CR S8071)
In the Congressional Record 10
Days the Record’s own index lists this bill, newest first, with the pages and the members it names. Pages starting H are the House, S the Senate, E Extensions of Remarks.
| Where | In the Record | Members | Date |
|---|---|---|---|
| Senate | Debate and remarks S8071–S8076, S8079, S8080 | Carl Levin D-MI, Dianne Feinstein D-CA, Elizabeth Warren D-MA, Harry Reid D-NV, John Boozman R-AR, John McCain R-AZ, Johnny Isakson R-GA, Lamar Alexander R-TN, Mark R. Warner D-VA, Richard Burr R-NC, Tom Coburn R-OK, Tom Harkin D-IA | Nov 18, 2013 |
| Senate | Debate and remarks S8013, S8024, S8026–S8030Amendments S8026, S8057Motions S8026Cloture motions S8027Lists S8025, S8028Organizations supporting H.R. 3204, Drug Quality and Security ActStaff and Senators who worked on H.R. 3204, Drug Quality and Security Act | Amy Klobuchar D-MN (cloture motion), Angus S. King Jr. I-ME (cloture motion), Barbara A. Mikulski D-MD, Benjamin L. Cardin D-MD (cloture motion), Bill Nelson D-FL (cloture motion), Christopher A. Coons D-DE (cloture motion), David Vitter R-LA, Debbie Stabenow D-MI (cloture motion), Harry Reid D-NV (amendment, cloture motion, motion), Jack Reed D-RI (cloture motion), Joe Manchin III D-WV (cloture motion), Mark Begich D-AK (cloture motion), Mark R. Warner D-VA (cloture motion), Michael F. Bennet D-CO, Pat Roberts R-KS, Patrick J. Leahy D-VT (cloture motion), Richard Blumenthal D-CT (cloture motion), Sheldon Whitehouse D-RI (cloture motion), Tim Kaine D-VA (cloture motion), Tom Coburn R-OK, Tom Harkin D-IA (cloture motion), Tom Udall D-NM (cloture motion) | Nov 14, 2013 |
| Senate | Debate and remarks S7965, S7967–S7970, S7974, S7981, S7984, S7985, S7986Amendments S8008Motions S7973 | Al Franken D-MN, David Vitter R-LA (amendment), Edward J. Markey D-MA, Harry Reid D-NV, Richard Burr R-NC, Tom Harkin D-IA | Nov 13, 2013 |
| Senate | Debate and remarks S7938, S7940–S7944Motions S7937Cloture motions S7949Recorded votes S7949cloture motion on motion to proceed | Al Franken D-MN (cloture motion), Barbara A. Mikulski D-MD (cloture motion), Barbara Boxer D-CA (cloture motion), Benjamin L. Cardin D-MD (cloture motion), Brian Schatz D-HI (cloture motion), Christopher A. Coons D-DE (cloture motion), Debbie Stabenow D-MI (cloture motion), Harry Reid D-NV (cloture motion, motion), Jeff Merkley D-OR (cloture motion), Kirsten E. Gillibrand D-NY (cloture motion), Lamar Alexander R-TN, Mark Begich D-AK (cloture motion), Patrick J. Leahy D-VT (cloture motion), Patty Murray D-WA (cloture motion), Richard J. Durbin D-IL (cloture motion), Sheldon Whitehouse D-RI (cloture motion), Tom Harkin D-IA (cloture motion), Tom Udall D-NM (cloture motion) | Nov 12, 2013 |
| Senate | Debate and remarks S7923Motions S7891Cloture motions S7923 | Al Franken D-MN (cloture motion), Barbara A. Mikulski D-MD (cloture motion), Barbara Boxer D-CA (cloture motion), Benjamin L. Cardin D-MD (cloture motion), Brian Schatz D-HI (cloture motion), Christopher A. Coons D-DE (cloture motion), Debbie Stabenow D-MI (cloture motion), Harry Reid D-NV (cloture motion, motion), Jeff Merkley D-OR (cloture motion), Kirsten E. Gillibrand D-NY (cloture motion), Mark Begich D-AK (cloture motion), Patrick J. Leahy D-VT (cloture motion), Patty Murray D-WA (cloture motion), Richard J. Durbin D-IL (cloture motion), Sheldon Whitehouse D-RI (cloture motion), Tom Harkin D-IA (cloture motion), Tom Udall D-NM (cloture motion) | Nov 7, 2013 |
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Congressional Budget Office cost estimate
- Sep 27, 2013H.R. 3204, the Drug Quality and Security ActAs posted on the website of the House of Representatives on September 26, 2013 (UPTON_006)
Constitutional authority
The sponsor’s statement, as printed in the page H5922.
CRS reports 13
Congressional Research Service work that CRS links to this bill or the law it became, newest first.
About this bill 1
Products that name it in their title: its number, its law number or one of its short titles.
| Product | Title | Kind | Published |
|---|---|---|---|
| R43290 | The Proposed Drug Quality and Security Act (H.R. 3204) Archived | Report | Oct 31, 2013 |
Also cite it 12
Products on other subjects that cite it, usually among other measures.
| Product | Title | Kind | Published |
|---|---|---|---|
| 97-1011 | Salaries of Members of Congress: Recent Actions and Historical Tables | Report | Nov 18, 2026 |
| R44576 | The Food and Drug Administration (FDA) Budget: Fact Sheet | Report | Jun 10, 2026 |
| R48649 | Expiring Health Provisions of the 119th Congress | Report | Sep 24, 2025 |
| R46507 | FDA’s Role in the Medical Product Supply Chain and Considerations During COVID-19 Archived | Report | Sep 1, 2020 |
| R41983 | How FDA Approves Drugs and Regulates Their Safety and Effectiveness | Report | May 8, 2018 |
Amendments 8
Amendments offered to this bill.
| Amendment | Description | Offered by | Status |
|---|---|---|---|
| SA 2007 | No description on file | Kirsten E. Gillibrand D-NY | Senate amendment submitted |
| SA 2008 | No description on file | Kirsten E. Gillibrand D-NY | Senate amendment submitted |
| SA 2024 | No description on file | David Vitter R-LA | Senate amendment submitted |
| SA 2033 | To change the enactment date. | Harry Reid D-NV | Proposed amendment SA 2033 withdrawn in Senate. (consideration: CR S8071) |
| SA 2034 | Of a perfecting nature. | Harry Reid D-NV | SA 2034 fell when SA 2033 withdrawn. (consideration: CR S8071) |
Related bills 3
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| S 957 | Drug Supply Chain Security Act | Related bill | May 15, 2013 |
| S 959 | Pharmaceutical Quality, Security, and Accountability Act | Related bill | Jun 19, 2013 |
| HR 1919 | Safeguarding America's Pharmaceuticals Act of 2013 | Related bill | Jun 4, 2013 |
Titles 11
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To amend the Federal Food, Drug, and Cosmetic Act with respect to human drug compounding and drug supply chain security, and for other purposes.
- Short Titles as Introduced
- Drug Quality and Security Act
- Short Titles as Passed House
- Drug Quality and Security Act
- Short Titles as Passed Senate
- Drug Quality and Security Act
- Short Titles as Enacted
- Drug Quality and Security Act
- Short Titles as Passed House for portions of this bill
- Drug Supply Chain Security Act
- Compounding Quality Act
- Short Titles as Passed Senate for portions of this bill
- Drug Supply Chain Security Act
- Compounding Quality Act
- Short Titles as Enacted for portions of this bill
- Drug Supply Chain Security Act
- Compounding Quality Act
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Administrative law and regulatory procedures
- Administrative remedies
- Advisory bodies
- Business records
- Computers and information technology
- Congressional oversight
- Consumer affairs
- Department of Health and Human Services
- Drug safety, medical device, and laboratory regulation
- Federal preemption
- Food and Drug Administration (FDA)
- Government information and archives
- Government studies and investigations
- Health
- Licensing and registrations
- Manufacturing
- Marketing and advertising
- Prescription drugs
- Public participation and lobbying
- Retail and wholesale trades
- Technology assessment
- Trade secrets and economic espionage
- User charges and fees
Text 4
Each version as it was printed, newest first.
- —Enrolled Bill
- Nov 5, 2013Placed on Calendar Senate
- Sep 28, 2013Engrossed in House
- Sep 27, 2013Introduced in House
Support LegiList
This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.